Robert Califf, MD, current deputy commissioner for medical products and tobacco at the FDA, has been nominated to lead the FDA and take over as commissioner. Margaret Hamburg, MD, stepped down from the position in February after nearly 6 years at the helm.
President Barack Obama has announced his nomination to lead the FDA: Robert Califf, MD, the current deputy commissioner for medical products and tobacco at the FDA. If the Senate confirms the nomination, Dr Califf would take the reins as the new commissioner for food and drugs.
In February, Margaret Hamburg, MD, announced she was stepping down, and since then Stephen Ostroff, MD, the FDA's chief scientist has filled the position. At the time, there had been speculation when Dr Califf's appointment with the FDA was first announced in January 2015 that he was part of the FDA's succession plan and would eventually become the next FDA commissioner.
“Dr Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalize on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years,” Dr Hamburg had
said in a statement upon Dr Califf’s appointment as deputy commissioner.
Dr Califf has spent most of his career in academia, having spent more than 30 years as a prominent cardiologist and medical researcher at Duke University. However, he has some experience with the FDA, having served on the agency's Cardiorenal Advisory Panel from 1996 to 2000 and its Science Board Working Group from 2007 to 2008.
Among the issues Dr Califf will have to tackle as commissioner are unfinished tobacco regulations, food safety and labeling reforms, and pressure from Republicans in Congress to streamline drug reviews.
The White House announced the nomination Tuesday along with a number of other officials being nominated for various federal positions.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More